Semaglutid · DOSSIER

Semaglutid

Semaglutide · Ozempic · Peptide · 31 AS
LEGAL DE · PRESCRIPTION-ONLYEVIDENCE · CLINICALLY ESTABLISHED3 STUDIES
SUMMARY

Helps the body release more insulin after meals — proven in large type-2-diabetes trials.

FIG.01 — SIGNAL CHAIN
EVIDENCE LEVELSPROVEN IN HUMANSANIMAL MODELS ONLYMECHANISM ONLYUNPROVEN IN HUMANS
01

What it does in the body

Findings, each with its evidence level — animal data kept visibly apart from what's unproven in humans.

Lowers blood sugar

Helps the body release more insulin after meals — proven in large type-2-diabetes trials.

PROVEN IN HUMANS
Less appetite, weight loss

Dampens hunger signals in the brain; participants lost significant weight in trials.

PROVEN IN HUMANS
Cardiovascular protection

In a large trial, fewer heart and circulatory events occurred than with placebo.

PROVEN IN HUMANS
Once-weekly dosing

Stays active in the blood for about 7 days — so one injection a week is enough.

MECHANISM ONLY
02

Mechanism of action

What Semaglutid does in the body — step by step.

01

Semaglutide is a synthetic analog of the body's own incretin hormone GLP-1 (glucagon-like peptide-1).

02

It binds with high affinity to the GLP-1 receptor in the pancreas, CNS and peripheral tissue.

03

In the pancreas, it enhances glucose-dependent insulin secretion and inhibits glucagon release.

03

Research status

How far along is the evidence?

PRECLINICALEARLY CLINICAL STUDIESCLINICALLY ESTABLISHED
Semaglutide is the most extensively clinically studied substance within the GLP-1 analog class.
Semaglutide is the most extensively clinically studied substance within the GLP-1 analog class.
The SUSTAIN study programme (8 Phase III studies, >8,000 subjects) established the substance in the context of type 2 diabetes.
SUSTAIN-6 (2016) showed a reduction in cardiovascular events compared with placebo.
The STEP programme (2021–2022) investigated semaglutide at higher doses in obesity and documented substantial reductions in body weight.
The FLOW programme (2024) investigated nephroprotective effects in diabetic kidney disease.
Current research is investigating possible effects on neurodegenerative diseases (EVOKE study, 2024).
04

Known risks

Without human data, safety statements are limited. What is known:

01
Gastrointestinal side effects: nausea, vomiting, diarrhoea — especially at the start of treatment (described in 20–40% of participants in clinical studies)
02
Pancreatitis risk: rare cases described in studies; contraindicated with a prior history
03
Possible association with thyroid carcinomas (in animal models; clinical relevance unclear)
04
Slowed gastric emptying can affect drug interactions
05
Ophthalmological complications: worsening of diabetic retinopathy described in SUSTAIN-6
06
Muscle loss possible with rapid weight loss (current research question)
07
Contraindication: personal or family history of medullary thyroid carcinoma or MEN2
05

Cited studies

Chronological — links lead to the source.

2016
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6)
PubMed 27633186 →
2021
Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)
PubMed 33567185 →
2023
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT)
PubMed 37952200 →
06

Frequently asked questions

What is Semaglutid?+

Semaglutide is a synthetic analog of the body's own incretin hormone GLP-1 (glucagon-like peptide-1).

What type of peptide is Semaglutid?+

Semaglutid belongs to the GLP-1 analog class.

What is Semaglutid used for?+

In research, Semaglutid has primarily been investigated in the context of: Metabolism. These are research findings (evidence: clinically established), not proven benefits in humans and not a usage recommendation.

Is Semaglutid legal in Germany?+

Semaglutid is prescription-only in Germany and may only be obtained with a medical prescription.

Is Semaglutid FDA-approved / legal in the US?+

Semaglutid is a prescription, FDA-approved medication in the US.

Is Semaglutid legal in Canada?+

Semaglutid is a prescription medication authorized by Health Canada.

Where can I buy Semaglutid?+

Peptica sells nothing and names no sources. Semaglutid is "prescription-only" in Germany; obtaining unapproved substances outside clinical studies is illegal and carries quality and safety risks.

What is the dosage of Semaglutid?+

Peptica publishes no dosing. Semaglutid is a prescription medicine — any dosing is determined individually by a physician. This is not medical advice.

Is Semaglutid banned in sport (WADA)?+

Semaglutid is currently not on the WADA Prohibited List.

What are the known risks of Semaglutid?+

Documented risks include: Gastrointestinal side effects: nausea, vomiting, diarrhoea — especially at the start of treatment (described in 20–40% of participants in clinical studies); Pancreatitis risk: rare cases described in studies; contraindicated with a prior history. This is not a complete safety assessment and not medical advice — see the risks section for the full list.

How well researched is Semaglutid?+

The evidence is classified as “clinically established”. 3 studies are cited on this page.

What is the molecular weight of Semaglutid?+

Semaglutid has a molar mass of about 4113.58 Da, with a plasma half-life of ~7 days.

Which peptides are related to Semaglutid?+

Closely related entries: Retatrutid, Tirzepatid. A direct side-by-side comparison is available via the compare function.

07

Dossier

Legal · Structure · Sources.

LEGAL STATUS BY REGION
Germanyprescription-only

Semaglutide is approved as a prescription-only medicine in the EU. Ozempic (2.4 mg/week s.c.) is approved for type 2 diabetes; Wegovy for obesity management. Rybelsus is the oral formulation (tablet) for type 2 diabetes. Obtaining it without a medical prescription is illegal in Germany (§ 48 AMG). Currently not on the WADA Prohibited List, but listed in the WADA monitoring programme.

Legal status varies by country and can change. This is not legal advice.

SOURCES & EXTERNAL DATABASES

Methodology: Peptica compiles publicly available studies and regulatory information and assigns each statement an evidence level. Not medical advice. No warranty.

RELATED PEPTIDES & FURTHER READING
08

Community notes

Note: These posts are user opinions and not medical advice. Posts containing dosages, therapeutic claims or purchase recommendations are removed. All entries are manually reviewed before publication.
This page is intended solely for factual, scientifically oriented information. No medical advice · no dosage or usage recommendations · no claims of efficacy · no substitute for medical consultation. Peptica sells no substances. Partner links are marked as advertising; Peptica may earn a commission. © 2026 Peptica · Issue 01